 - Determine whether the addition of bevacizumab to the docetaxelanthracycline-based regimens docetaxel with AC, docetaxelcapecitabine with AC, and docetaxelgemcitabine hydrochloride with AC will increase the rate of cCR compared to the same docetaxelanthracycline-based regimens without bevacizumab in these patients. 